Table 3.

Incidence of AD Associated With High vs Low Exposure to Statins^a

Statin Type	Hazard Ratio (95% CI)
	All	P Value	White	P Value	Hispanic	P Value	Black	P Value
Women
All	0.85 (0.82–0.89)	<.001	0.86 (0.82–0.89)	<.001	0.88 (0.77–1.01)	.06	0.82 (0.73–0.92)	<.001
Simvastatin	0.85 (0.81–0.90)	<.001	0.86 (0.81–0.92)	<.001	0.82 (0.68–0.99)	.04	0.78 (0.66–0.93)	.01
Atorvastatin	0.82 (0.77–0.87)	<.001	0.84 (0.78–0.89)	<.001	0.76 (0.60–0.97)	.02	0.81 (0.67–0.98)	.03
Pravastatin	0.82 (0.71–0.95)	.01	0.82 (0.70–0.95)	.01	0.82 (0.48–1.39)	.46	0.76 (0.43–1.32)	.33
Rosuvastatin	0.83 (0.70–0.97)	.02	0.81 (0.67–0.98)	.03	1.17 (0.78–1.75)	.44	0.67 (0.36–1.26)	.22
Men
All	0.88 (0.83–0.93)	<.001	0.89 (0.84–0.95)	<.001	0.71 (0.58–0.88)	.001	0.86 (0.69–1.07)	.18
Simvastatin	0.87 (0.80–0.94)	.001	0.90 (0.82–0.99)	.02	0.67 (0.50–0.91)	.01	0.77 (0.55–1.07)	.12
Atorvastatin	0.90 (0.82–0.99)	.02	0.92 (0.83–1.02)	.11	0.61 (0.42–0.89)	.01	0.92 (0.63–1.33)	.64
Pravastatin	0.78 (0.63–0.97)	.03	0.82 (0.65–1.04)	.11	0.75 (0.29–1.89)	.54	0.70 (0.25–1.95)	.50
Rosuvastatin	0.90 (0.70–1.16)	.40	0.88 (0.66–1.17)	.38	1.00 (0.51–1.97)	.99	1.53 (0.54–4.33)	.42

Abbreviation: AD, Alzheimer disease.

^aHazard ratios depicting relative risk of AD incidence during 2009 to 2013 for those with high exposure to statins, compared with low exposure. High-exposure individuals are those with days of filled prescriptions in at least the 50th percentile of days in the mean statin-year in at least 2 years of 2006, 2007, and 2008. The low-exposure group used the designated statin, but for fewer days, or later in the sample period.